Market research
ZEGA.F AstraZeneca PLC
F EUR Healthcare
Latest close
As of 01 Mar 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 234B
- P/E ratio
- 30.08
- Analyst target
- 69.28
- Dividend yield
- 4.0%
- Beta
- 0.19
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- ISIN
- Not available
- Market cap
- 234B
- P/E ratio
- 30.08
- Analyst target
- 69.28
- Dividend yield
- 4.0%
- Beta
- 0.19
About
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. It has a strategic agreement with Tempus to develop the largest multimodal foundation model in oncology. The company has a collaboration agreement with IonQ, Inc. for the development of quantum-accelerated computational chemistry workflow for healthcare, life sciences, and chemistry; a strategic research collaboration with CSPC Pharmaceutical Group Limited to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications and multiple next-generation therapies for obesity and type 2 diabetes; and collaboration Revna Biosciences for lung cancer treatment. AstraZeneca PLC was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the Uni
Research context
AstraZeneca PLC appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ZEGA.F discussion.
5 years, 6 months ago
AstraZeneca PLC is currently in a long term uptrend where the price is trading 13.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.8.
AstraZeneca PLC's total revenue rose by 11.2% to $7B since the same quarter in the previous year.
Its net income has increased by 223.3% to $1B since the same quarter in the previous year.
Finally, its free cash flow grew by 44.9% to $1B since the same quarter in the previous year.
Based on the above factors, AstraZeneca PLC gets an overall score of 5/5.